Form 4: Akebia Therapeutics SVP Michel Dahan Sells Shares to Cover Tax Obligations
SEC Form 4
Michel Dahan, SVP and Chief Operating Officer of Akebia Therapeutics, sold 34,840 shares of common stock on May 13, 2024, to cover tax withholding obligations related to vesting restricted stock units.
Summary
- Michel Dahan, SVP and Chief Operating Officer of Akebia Therapeutics, sold 34,840 shares of common stock on May 13, 2024.
- The shares were sold at a price of $1.26 per share.
- The sale was made automatically by the issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units granted on May 12, 2023.
- The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Dahan on December 3, 2023.
- Following the transaction, Dahan beneficially owns 672,092 shares of Akebia Therapeutics common stock.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a routine transaction related to tax obligations and a pre-existing trading plan.
Industry Context
This is a routine Form 4 filing related to an insider stock sale to cover tax obligations. It's common for executives to use Rule 10b5-1 trading plans to avoid accusations of insider trading.
Stakeholder Impact
- The sale of shares by an executive could be perceived negatively by some shareholders, but the pre-arranged nature of the sale mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 2023-05-12 | Date of grant of restricted stock units to Michel Dahan. |
| 2023-12-03 | Date Michel Dahan adopted the Rule 10b5-1 trading plan. |
| 2024-05-13 | Date of the stock sale transaction. |
| 2024-05-14 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.